Located in the Finnish population, a rare variant of the Tyrobp gene increases the risk of Alzheimer’s disease, a new study led by the University of East Finland’s broadcasts. This gene variant affects the function of the microtics, the cells that regulate inflammation in the brain. The findings further confirm the role of the altered inflammatory response and the reaction of stress protein in the early stages of Alzheimer’s disease.
The Finnish heritage of the disease contains genetic disorders that are extremely rare in other parts of the world. One such disorder is Nasu-Hakola’s disease characterized by bone cysts as well as personality changes and dementia that begins between the ages of 30 to 40 years. Tyrobp gene. The disease is inherited with intensity, that is, manifested only if the deletion is inherited by both parents. However, it was previously assumed that the only carriers, who inherit the deletion of a single parent, would not be affected. Now the new study shows that his carriers Tyrobp Delete have a significantly increased risk of Alzheimer’s disease.
Alzheimer’s disease is the most common progressive memory disorder, with in recent years seeing the discovery of many new risk genes. On the brain tissue, many of them are mainly expressed in microtics. Researchers have shown, for the first time, that the single -ally deletion in Tyrobp The gene expressed in microtics is also associated with an increased risk of Alzheimer’s disease. The gene variant also led to a previous appearance of the disease, by two years on average, compared to people who do not convey the deletion.
The union of Tyrobp The gene with Alzheimer’s disease has not been observed before, because Tyrobp Variations are extremely rare worldwide. The deletion of Tyrobp The gene occurs almost exclusively in the Finns.
The Finnish Finngen Project has compiled genetic and health data of half a million Finnish bio -constructive sample donors, providing a unique set of data for our research. “
Henna Martiskainen, Research Fellow, Biomedical Institute, University of East Finland
To explore the mechanisms of the disease, elderly asymptomatic people from East Finland Biobank were reconnected for the study based on their genetic data. Cellular models produced by blood samples Tyrobp Carriers and deletion controls were used to explore the effects of gene variant. Cells from Tyrobp Elimination carriers and those with Nasu-Hakola disease have shown a higher inflammatory response and a lower reaction of endoplasmic network compared to witnesses. The study suggests that while Nasu-Hakola and Alzheimer’s disease share some common biological mechanisms, they also have unique. Determination of these mechanisms can help develop therapies for both conditions. THE Tyrobp The gene produces a protein called DAP12 associated with the TREM2 signaling road, which regulates the function of microglies and is currently a focus on the development of drugs for Alzheimer’s disease.
“With effective treatments for Alzheimer’s disease available in the future, the genetic background of humans can affect the choice of treatment. Therefore, it is important to know the variations that predispose the future population to patients with Alzheimer’s and our action mechanism.
“This study is a new opening in a continuous based on the pioneering work of Professor Panu Hakola, who first reported Nasu-Hakola’s disease and other Finnish researchers over the years.
The study was conducted in collaboration between Kuopio University Hospital and Oulu University Hospital and is part of research projects funded by the Finland Research Council and the Sigrid Jusélius Foundation.
Source:
Magazine report:
Martiskainen, H., et al. (2025). Tyrobp single deletion is a new risk factor for Alzheimer’s disease. Molecular neurodegeneration. Doi.org/10.1186/s13024-025-00830-3.
